COMMUNIQUÉS West-GlobeNewswire
-
Cannabix Technologies Announces Detection of Fentanyl in Human Breath
09/11/2026 -
NeOnc CEO Adds Another 70,000 Shares as Insider Buying Continues
09/11/2026 -
Vireo Growth Inc. Completes Acquisition of FLUENT Corp.
09/11/2026 -
Biodexa provides R&D Update
09/11/2026 -
Veru to Present New Results on Effects of Enobosarm on Physical Function in Older Patients Receiving GLP-1 RA from the Phase 2b QUALITY clinical study at ObesityWeek 2026
09/11/2026 -
Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
09/11/2026 -
Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200
09/11/2026 -
Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
09/11/2026 -
Profound Medical to Participate in the Stifel 2026 Healthcare Conference
09/11/2026 -
Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors
09/11/2026 -
Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference
09/11/2026 -
BridgeBio to Participate in November and December Investor Conferences
09/11/2026 -
PharmAla Biotech Signs Supply and Data Agreement with Aalborg University Hospital for Danish Randomized Trial of MDMA-Assisted Treatment for Service-Related PTSD
09/11/2026 -
Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
09/11/2026 -
Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
09/11/2026 -
Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in London
09/11/2026 -
CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
09/11/2026 -
Novo Nordisk A/S - share repurchase programme
09/11/2026 -
Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update
09/11/2026
Pages